Fig 5 -

<p>Viral neutralization and antibody pharmacokinetics (represented by means ± SEMs) in CVLs in Segments A and B (Active film group only). Neutralization percent is represented by solid lines/circles () (left <i>y</i> axis), and antibody concentration is represented by dashed lines/open triangles () (right <i>y</i> axis) in each graph. (<b>A).</b> VRC01-N concentration and HIV_Q23-17 neutralization in Segment A were significantly increased at 24 hours post single film insertion compared to both Baseline (<i>p</i> = 0.006 and 0.01, respectively) and 7 days post single film insertion (<i>p</i> = 0.006 and 0.02, respectively). (<b>B).</b> HSV8-N concentrations in Segment A were significantly increased at 24 hours post single film insertion compared to both Baseline (<i>p</i> = 0.04) and 7 days post single film insertion (<i>p</i> = 0.01). All CVL samples from 24 hours post film insertion exhibited 100% HSV neutralization; however, the omnibus F test <i>p</i>-value did not reach statistical significance (<i>p</i> = 0.052). (<b>C).</b> VRC01-N concentration and HIV_Q23-17 neutralization in Segment B were significantly elevated 24 hours after first film and 24 hours after seventh film compared to Baseline (<i>p</i> < 0.001 for all comparisons). (<b>D).</b> In Segment B, HSV8-N concentrations 24 hours after first film and 24 hours after seventh film did not differ significantly from Baseline (<i>p</i> = 0.056, Group x Visit interaction), but HSV neutralization was significantly increased at 24 hours post first film (<i>p</i> = 0.003) and 24 hours post seventh film compared to Baseline (<i>p</i> = 0.001).</p>